APC Annexin V

Pricing & Availability
Regulatory Status
RUO
Other Names
Annexin A5
Ave. Rating
Submit a Review
Product Citations
publications
APC_Annexin-V_kit_052318_non-apop
Human T leukemia cell line Jurkat, treated (left) or non-treated (right) with BioLegend’s anti-human CD95 (EOS9.1) mAb (Cat. No. 305704) for 4 hours, then stained with Annexin V- APC and Helix NP Green (Cat. No. 425303 at 5 nM) in Annexin V Binding buffer for 15 minutes at 25°C.
  • APC_Annexin-V_kit_052318_non-apop
    Human T leukemia cell line Jurkat, treated (left) or non-treated (right) with BioLegend’s anti-human CD95 (EOS9.1) mAb (Cat. No. 305704) for 4 hours, then stained with Annexin V- APC and Helix NP Green (Cat. No. 425303 at 5 nM) in Annexin V Binding buffer for 15 minutes at 25°C.
See APC spectral data
Cat # Size Price Quantity Check Availability Save
640919 25 tests $102
Check Availability


Need larger quantities of this item?
Request Bulk Quote
640920 100 tests $220
Check Availability


Need larger quantities of this item?
Request Bulk Quote
640941 300 tests $444
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Annexin V (or Annexin A5) is a member of the annexin family of intracellular proteins that binds to phosphatidylserine (PS) in a calcium-dependent manner. PS is normally only found on the intracellular leaflet of the plasma membrane in healthy cells, but during early apoptosis, membrane asymmetry is lost and PS translocates to the external leaflet. Fluorochrome-labeled Annexin V can then be used to specifically target and identify apoptotic cells. Annexin V Binding Buffer (Cat. No. 422201) is recommended for use with Annexin V staining. Annexin V binding alone cannot differentiate between apoptotic cells and necrotic. Therefore, we recommend using our Helix NP™ Blue (Cat No. 425305), Helix NP™ Green (Cat No. 425303) or Helix NP™ NIR (Cat. No. 425301). Early apoptotic cells will exclude 7-AAD and PI, while late stage apoptotic cells and necrotic cells will stain positively, due to the passage of these dyes into the nucleus where they bind to DNA.

Product Details
Technical data sheet

Product Details

Verified Reactivity
All mammalian species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The purified protein was conjugated with APC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The Annexin V solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per 100,000 - million cells in a 100 µl volume of Annexin V Binding Buffer (Cat No. 422201). It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Annexin V Staining
1. Wash cells twice with cold BioLegend Cell Staining Buffer (Cat. No. 420201) and then resuspend cells in Annexin V Binding Buffer (Cat. No. 422201) at a concentration of 1x106 cells/ml.
2. Transfer 100 µl of cell suspension in 5 ml test tube.
3. Add 5 µl of APC Annexin V.
4. Add 10 µl of PI solution (Cat. No. 421301) or 7-AAD (Cat. No. 420403/420404).
5. Gently vortex the cells, and incubate for 15 min at room temperature (25°C), in the dark.
6. Add 400 µl of Annexin V Binding Buffer (Cat. No. 422201) to each tube. Analyze by flow cytometry.


For a better experience detecting apoptosis, we now recommend Apotracker™. Cell staining with Apotracker™ is Calcium independent. Thus, no special buffers are required, and the protocol can be shortened for single-step co-staining with other reagents

Application References

(PubMed link indicates BioLegend citation)
  1. Koopman G, et al. 1994. Blood 84:1415.
  2. Vermes I, et al. 1995. J. Immunol. Methods 184:39.
  3. Dachary-Prigent J, et al. 1993. Blood 81:2554.
  4. Sekine C, et al. 2009. Int Immunol. PubMed
  5. Grujic M, et al. 2010. J. Immunol. 185:1730. PubMed
  6. Hussain MS, et al. 2013. Hum Mol Genet. 22:5199. PubMed
  7. Feng Q, et al. 2014. PLoS One. 9:95927. PubMed
  8. Isobe T, et al. 2014. eLife. 3:1977. PubMed
Product Citations
  1. Isobe T, et al. 2014. Elife. 3:1977. PubMed
  2. Tang Z, et al. 2017. Cell Death Differ. 24:2127. PubMed
  3. Patel RP, et al. 2020. Transl Oncol. 14:100917. PubMed
  4. Preda MB, et al. 2021. Cell Death Dis. 12:566. PubMed
  5. Chugh RM, et al. 2021. Stem Cell Res Ther. 12:388. PubMed
  6. Inclan-Rico JM, et al. 2020. Nat Immunol. 21:1181. PubMed
  7. McCartin C, et al. 2022. Cancers (Basel). 14:. PubMed
  8. Xu B, et al. 2017. Oncogenesis. 6:e295. PubMed
  9. Wu N, et al. 2020. Cell Rep. 30:1129. PubMed
  10. Wiley CD, et al. 2019. Cell Rep. 28:3329. PubMed
  11. Kuljanin M, et al. 2018. Cell Rep. 25:2524. PubMed
  12. Wu SJ, et al. 2017. Cell Rep. 2.628472222. PubMed
  13. Schick M, et al. 2022. Nat Commun. 13:281. PubMed
  14. Dai X, et al. 2017. J Cell Mol Med. 10.1111/jcmm.13296. PubMed
  15. Donado CA, et al. 2020. Cell Reports. 31(1):107466. PubMed
  16. Cannons JL, et al. 2021. Cell Rep. 37:109804. PubMed
  17. Zeriouh W, et al. 2017. PLoS One. 12(2):e0170823. PubMed
  18. Weiser J, et al. 2015. J Infect Dis. 212: 1677 - 1682. PubMed
  19. Zhang S, et al. 2019. Front Pediatr. 0.485416667. PubMed
  20. Vig S, et al. 2019. Cell Death Dis. 0.63125. PubMed
  21. Xiao C, et al. 2022. iScience. 25:103934. PubMed
  22. McNeal AS, et al. 2021. Elife. 10:. PubMed
  23. Wang J, et al. 2016. Nat Cell Biol. 18: 480-490. PubMed
  24. Sumitomo Y, et al. 2016. Blood. 128: 1614 - 1624. PubMed
  25. Li L, et al. 2016. Cell Death Dis. 7:e2439. PubMed
  26. Wohlhieter CA, et al. 2020. Cell Rep. 33:108444. PubMed
  27. Pease NA, et al. 2021. Cell Reports. 34(12):108888. PubMed
  28. Cao J, et al. 2019. Theranostics. 0.938194444. PubMed
  29. Moose DL, et al. 2020. Cell Rep. 30:3864. PubMed
  30. Figueroa-Valdés AI, et al. 2021. Front Bioeng Biotechnol. 9:619930. PubMed
  31. Fujino T, et al. 2021. Nat Commun. 12:1826. PubMed
  32. Patel RP, et al. 2021. Invest Ophthalmol Vis Sci. 62:16. PubMed
  33. Dregalla RC, et al. 2021. Stem Cell Res Ther. 12:547. PubMed
  34. Linnerbauer M, et al. 2022. Front Immunol. 12:800128. PubMed
  35. Vongpipatana T, et al. 2020. J Immunol. 2156:204. PubMed
  36. O'Neill K, et al. 2016. Genes Dev. 30: 973-988. PubMed
  37. Hussain M, et al. 2013. Hum Mol Genet. 22:5199. PubMed
  38. Zeng H, et al. 2018. Cancer Cell. 34:56:00. PubMed
  39. Lei W, et al. 2020. Sci Rep. 10:7004. PubMed
  40. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
  41. Deng J, et al. 2021. Cell Death Dis. 12:978. PubMed
  42. Hickman O, et al. 2016. Br J Cancer. 10.1038/bjc.2016.91. PubMed
  43. Laughney AM, et al. 2020. Nat Med. 26:259. PubMed
  44. Hagan AS, et al. 2020. Development. 147:00:00. PubMed
  45. Sheng Y, et al. 2019. Cell Prolif. 52:e12611. PubMed
  46. Tang Z, et al. 2019. Cell Rep. 28:1744. PubMed
  47. Liu L, et al. 2019. Cell Prolif. :e12718. PubMed
  48. Fleischmann M, et al. 2021. Cells. 10:. PubMed
  49. Rausch M, et al. 2021. Cancers (Basel). 13:. PubMed
  50. Lee M, et al. 2022. Nat Commun. 13:1157. PubMed
  51. Høgh RI, et al. 2020. J Immunol. 1746:204. PubMed
  52. Zhang S, et al. 2020. Front Immunol. 1.757638889. PubMed
  53. Saint Fleur–Lominy S, et al. 2018. Cell Rep. 24:3045. PubMed
  54. Kanda K, et al. 2018. JCI Insight. 3:e91316. PubMed
  55. Zhou X, et al. 2019. Cell Rep. 27:1176. PubMed
  56. Lee Y, et al. 2022. Sci Adv. 8:eabm7688. PubMed
  57. Qiu C, et al. 2022. Front Immunol. 12:764949. PubMed
  58. Aslam MA, et al. 2021. EMBO Rep. 22:e51184. PubMed
  59. Cao W, et al. 2016. Nat Commun. 7:11687. PubMed
  60. Perny M, et al. 2016. Cell Death Dis. 7:e2447. PubMed
  61. Liu L, et al. 2020. Cancer Res. 80:2564. PubMed
  62. Brasacchio D, et al. 2018. Cell Death Dis. 0.681944444. PubMed
  63. Celus W, et al. 2021. Cancer Immunol Res. Online ahead of print. PubMed
  64. Cai J, et al. 2021. eLife. 10:00. PubMed
  65. Cheng CC, et al. 2020. Elife. 9:00. PubMed
  66. Feng Q, et al. 2014. PLoS One. 9:95927. PubMed
  67. Jung E, et al. 2017. J Neurosci. 37:6837. PubMed
  68. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  69. Warmuth S, et al. 2022. Oncoimmunology. 10:2004661. PubMed
  70. Hills LB, et al. 2021. J Immunol. 206:89. PubMed
  71. Dou R, et al. 2021. Cell Death Dis. 12:206. PubMed
  72. Burclaff J, et al. 2022. Cell Mol Gastroenterol Hepatol. 13:1554. PubMed
  73. Pedicona F, et al. 2022. Sci Signal. 15:eabl7989. PubMed
  74. Li R, et al. 2022. Exp Hematol Oncol. 11:77. PubMed
  75. He C, et al. 2022. BMC Cancer. 22:1100. PubMed
  76. Li C, et al. 2021. Cell Metabolism. 33(8):1610-1623.e5. PubMed
  77. Kostadinova E, et al. 2016. Sci Rep. 6:30943. PubMed
  78. Qiu Z, et al. 2019. Theranostics. 3.650694444. PubMed
  79. Reyes–Uribe P, et al. 2018. Oncogene. 37:4058. PubMed
  80. Lima S, et al. 2018. Autophagy. 1.2375. PubMed
  81. Oh J, et al. 2017. PLoS Biol. 15:e2003352. PubMed
  82. Lasrado N, et al. 2022. iScience. 25:103865. PubMed
  83. Forsberg MH, et al. 2021. Stem Cell Res Ther. 12:459. PubMed
  84. Okita R, et al. 2021. Thorac Cancer. 12:775. PubMed
  85. Fernández D, et al. 2016. PLoS One. 11: 0157889. PubMed
  86. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  87. Pothlichet J, et al. 2020. J Clin Invest. 130:2872. PubMed
  88. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  89. Sun J et al. 2018. Cell stem cell. 23(3):355-369 . PubMed
  90. Sharma P, et al. 2018. Data Brief. 1.975694444. PubMed
  91. Li B, et al. 2019. Oncol Rep. 41:608. PubMed
  92. Millington-Burgess SL, et al. 2021. Sci Rep. 11:17678. PubMed
  93. Sahoo SS, et al. 2021. Nat Med. 27:1806. PubMed
  94. Hirata SI, et al. 2020. Allergy. 75:1939. PubMed
  95. Vickman R, et al. 2016. Mol Cancer Res. 14: 776 - 786. PubMed
  96. Cabet E, et al. 2015. PLoS One. 10: 0137009. PubMed
  97. Burgener SS, et al. 2019. Cell Rep. 27:3646. PubMed
  98. Hasselluhn MC, et al. 2019. Cell Death Dis. 0.726388889. PubMed
  99. Zhang S, et al. 2018. Sci Rep. 8:17066. PubMed
  100. Shinde R, et al. 2018. Nat Immunol. 1.188194444. PubMed
  101. Rodriguez-Perdigon M, et al. 2022. Macromol Biosci. 22:e2200168. PubMed
  102. Xu Y, et al. 2021. IUBMB Life. 73:1432. PubMed
  103. Ho JY, et al. 2021. Mol Ther Methods Clin Dev. 21:237. PubMed
  104. Yamamoto H, et al. 2016. Sci Rep. 6:19204. PubMed
  105. Dong G, et al. 2020. Haematologica. . PubMed
  106. Alamillo E, et al. 2017. Fish Shellfish Immunol. 10.1016/j.fsi.2017.08.036. PubMed
  107. Voss OH, et al. 2018. Curr Protoc Immunol. 120:14.44.1. PubMed
  108. Dower CM, et al. 2018. Mol Cancer Ther. 2.350694444. PubMed
  109. Barve A, et al. 2019. Cells. 1.251388889. PubMed
  110. Tulasi DY, et al. 2021. Cell Mol Gastroenterol Hepatol. 11:1437. PubMed
  111. Satcher R, et al. 2015. J Cell Sci. 128: 4629 - 4641. PubMed
  112. Grossman L, et al. 2017. mSphere. 2:e00305. PubMed
  113. Habtetsion T et al. 2018. Cell metabolism. 28(2):228-242 . PubMed
  114. Woolf N, et al. 2017. Oncogenesis. 10.1038/oncsis.2017.77. PubMed
  115. Parsa S, et al. 2021. Nat Cancer. 1:653. PubMed
  116. Li S, et al. 2021. Front Pharmacol. 12:634115. PubMed
  117. Höhne K, et al. 2016. Open Bio. 6: 160046. PubMed
  118. Festag J, et al. 2020. Mol Ther Nucleic Acids. 1.330555556. PubMed
  119. Wallace JG, et al. 2020. Clin Immunol. 210:108311. PubMed
  120. Cordo' V, et al. 2022. Nat Commun. 13:1048. PubMed
  121. Mykhailova O, et al. 2021. Transfusion. 61:1247. PubMed
  122. Walle T, et al. 2022. Sci Adv. 8:eabh4050. PubMed
  123. Loo Yau H, et al. 2021. Molecular Cell. 81(7):1469-1483.e8. PubMed
  124. Viviane Ponath, Bernd Kaina 2017. PLoS One. 10.1371/journal.pone.0170347. PubMed
  125. Yang X, et al. 2020. Immunity. 51(6):983-996.e6.. PubMed
  126. Chen Y, et al. 2020. Front Oncol. 10:767. PubMed
  127. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  128. Agarwal P, et al. 2021. Cell Reports. 36(2):109386. PubMed
  129. Song S, et al. 2021. Mar Drugs. 19: . PubMed
  130. Schäfer AL, et al. 2021. Front Immunol. 12:696810. PubMed
  131. Anderson CJ, et al. 2021. Nature. 596:262. PubMed
  132. Trigg RM, et al. 2019. Nat Commun. 4.186111111. PubMed
  133. Young MM, et al. 2019. Cell Death Dis. 1.004861111. PubMed
  134. Chen Y, et al. 2022. Cell Death Dis. 13:822. PubMed
  135. Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed
RRID
not an antibody (BioLegend Cat. No. 640919)
AB_2561515 (BioLegend Cat. No. 640920)
AB_2616657 (BioLegend Cat. No. 640941)

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
308 View all products for this Gene ID
UniProt
View information about Annexin V on UniProt.org

Related FAQs

How is your Annexin made and what sequence does it cover?

It is made in E. coli, covering human aa Met1-Asp320.

How does pH and staining temperature affect Annexin V-Phosphatidylserine binding?

Annexin-Phosphatidylserine binding is lost below pH 5.2 and with prolonged incubation over a temperature of 42°C.

Why do I need to use Annexin V Binding Buffer?

Annexin V binding requires the presence of calcium in the solution.  So, we provide Annexin V Binding Buffer (cat # 422201), which is optimized for the best performance of Annexin V staining.

Can I use RPMI during Annexin V staining?

It is best to follow protocol as described on the product data sheet. Moreover, RPMI 1640 has a relatively high concentration of phosphate and low calcium ion concentration, which negatively impacts Annexin binding to its target phosphatidylserine (PS). Measurement of cell death by using Annexin V may also be significantly affected by time of incubation on ice, calcium concentration, and type of medium.

Can I freeze Annexin V conjugates?

It should not be frozen as it will lead to loss of biological activity due to dimerization.

Is Annexin V suitable for conjugation with the Maxpar® kit for CyTOF®?

Maxpar® Labeling kits require the protein to be partially reduced, so the metal chelate can be introduced through an SH group in the hinge region of the reduced antibody. Human Annexin V contains only one Cysteine which was reported to be chemically inactive. Thus, the Maxpar® labeling protocol would not work with Annexin V, unless a free –SH group can be introduced to Annexin V.  For more information regarding SH-mediated conjugation of Annexin V please consult published papers such as this one.

Go To Top Version: 6    Revision Date: 04/20/2020

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login/Register
Remember me
Forgot your password? Reset Password
Request an Account